Baraliakos, Xenofon
Saffore, Christopher D.
Collins, Eric B. http://orcid.org/0000-0002-9329-847X
Parikh, Bhumik
Ye, Xiaolan
Walsh, Jessica A.
Funding for this research was provided by:
AbbVie
Article History
Received: 10 May 2024
Accepted: 24 May 2024
First Online: 10 June 2024
Declarations
:
: Xenofon Baraliakos has received grant/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB Pharma; speakers’ bureau fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB Pharma; is an editorial board member of the <i>Annals of Rheumatic Diseases</i>; is the ASAS President; and is the EULAR President-elect. Christopher D. Saffore is an employee of AbbVie Inc. and may hold stock. Eric B. Collins is an employee of Medicus Economics LLC, which received consulting fees and research support from AbbVie. Bhumik Parikh is an employee of AbbVie Inc. and may hold stock. Xiaolan Ye is an employee of AbbVie Inc. and may hold stock. Jessica A. Walsh has received consulting fees or research grants from AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB Pharma.
: This publication is based on previously conducted clinical trials and no new clinical trials with human participants or animals were performed by any of the authors.